San Diego, United States
VedaBio, established in 2021, is a pioneering entity in the Biotechnology sector, headquartered in the United States. With the slogan "Unlocking the true power of CRISPR for molecular detection," the company stands at the intersection of cutting-edge science and impactful innovation.
Prominent for its groundbreaking platform in molecular biology, VedaBio focuses on near-instant molecular detection that does not require target amplification, setting a new benchmark in accuracy for highly multiplexed analytes. By leveraging CRISPR technology, the company is poised to revolutionize the field with quicker and more precise diagnostic capabilities.
Recent financial backing underscores the confidence investors place in VedaBio's vision and technology. The company secured a $40.00M Series A investment on 17 October 2023 from key investors OMX Ventures and Kleinmuntz Associates. This capital infusion is expected to bolster their research and development efforts, propelling their growth trajectory.
